Balanced news tone
News Sentiment
COPN sentiment intelligence
Cosmo N.V. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
86/100 classification confidence.
directly relevant articles
high-authority source matches
-8.8% over one week, -8.0% over four weeks, trend inactive, and near fair-value range.
Cosmo schedules July 23 results webcast, with CEO and CFO on call
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Cosmo schedules July 23 results webcast, with CEO and CFO on call
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Jun 2026 07:00
- Source
- Stock Titan
Cosmo Pharmaceuticals NV Actuals & Estimates (SIX:COPN)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 07:56
- Source
- TradingView
How Winlevi’s Europe Launch At Cosmo (SWX:COPN) Has Changed Its Investment Story
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jun 2026 07:00
- Source
- simplywall.st
Cosmo N.V. (SWX:COPN) Valuation Check As Winlevi Launch Advances Across Europe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- simplywall.st
Cosmo N.V.: Target Price Consensus and Analysts Recommendations | COPN | NL0011832936
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 18 Apr 2026 04:23
- Source
- marketscreener.com
Is It Too Late To Consider Cosmo Pharmaceuticals (SWX:COPN) After A 75% One Year Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Mar 2026 07:00
- Source
- Market source
Is It Time To Reassess Cosmo Pharmaceuticals (SWX:COPN) After The Recent Share Price Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Mar 2026 07:00
- Source
- simplywall.st
Cosmo Pharmaceuticals (SWX:COPN) Swings To Loss And Tests Bullish Profitability Narratives
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Mar 2026 07:00
- Source
- simplywall.st
Cosmo Pharmaceuticals Achieves 104.2M Revenue and 9.5M EBITDA in 2025; Proposes 2.10 Dividend; Establishes 2026 Growth Framework
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 08 Mar 2026 08:00
- Source
- TradingView
Assessing Cosmo Pharmaceuticals (SWX:COPN) Valuation After Strong Multi Year Returns And Recent Share Price Pullback
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 24 Feb 2026 08:00
- Source
- Market source
Private companies are Cosmo Pharmaceuticals N.V.'s (VTX:COPN) biggest owners and were rewarded after market cap rose by CHF61m last week
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jan 2026 08:00
- Source
- simplywall.st
Cosmo Pharmaceuticals N.V. (VTX:COPN) Stocks Shoot Up 35% But Its P/E Still Looks Reasonable
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Dec 2025 08:00
- Source
- simplywall.st
Cosmo shares surge over 20% after Breezula Phase III trials hit key goals
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Dec 2025 08:00
- Source
- Investing.com
COSMO PHARMACEUTICALS NV stock price at wienerborse.at/en
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Sep 2024 15:36
- Source
- Wiener Börse
Cosmo Pharmaceuticals N.v Stock Price Forecast. Should You Buy COPN.SW?
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 16 Dec 2020 12:32
- Source
- StockInvest.us